

Special Issue

Personalized Diagnostics, Treatment, and Outcomes of Chronic Kidney Diseases

Message from the Guest Editor

Chronic kidney disease is one of the most potent risk factors for end-stage kidney disease. The number of patients with chronic kidney disease is increasing. Although several new drugs have been launched in clinical practice, the global need for optimal strategies to prevent the progression of chronic kidney disease urgently needs to be addressed. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of the science and present the latest findings in the field of chronic kidney disease. We call for research that explores all conditions associated with chronic kidney disease, using basic science, clinical- and population-based approaches, and all kinds of actions for public awareness. Scientific advancements in the field of chronic kidney disease promise a brighter future for patients.

Guest Editor

Prof. Dr. Haruhito A. Uchida

Department of Chronic Kidney Disease and Cardiovascular Disease,
Okayama University Faculty of Medicine, Dentistry and Pharmaceutical
Sciences, Okayama, Japan

Deadline for manuscript submissions

closed (30 June 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/173756

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).